The company is rebranding itself to better align with its broader market focus on both transplant and oncology diagnostics. OncoCyte has completed the design of its clinical molecular diagnostic testing kit and secured approval from a major institutional review board, with plans to involve three of the top ten U.S. transplant centers in an upcoming clinical trial.
Cyborg Score Rationale
Q1 2025 revenue reached $2.1 million in pharma services with a 62% gross margin, a significant increase from the previous quarter. However, the company remains pre-commercialization for its lead transplant diagnostic test and operates with significant losses, positioning it as a clinical-stage developer in a capital-intensive space.
Top Insights
Company rebranded to Insight Molecular Diagnostics Inc. (ticker: IMDX) and relocated headquarters from Irvine, California to Nashville, Tennessee as of June 2025.
Ten leading transplant hospitals are utilizing GraftAssure research-use-only kits with plans to have at least 20 centers using these by year-end 2025.
New reimbursement rates for GraftAssureCore strengthen the company's position in the growing transplant rejection testing market.
Portfolio includes DetermaIO for immunotherapy response prediction, DetermaCNI for cancer treatment monitoring, and VitaGraft for transplant testing, plus pharma services for biomarker discovery and clinical trial support.
Named Competitors
Liquid Biopsy & Cancer Detection — Plasma-based comprehensive cancer genomics testing
Transplant Monitoring — ddPCR technology partner for transplant diagnostics
Cancer Genomics Testing — Tumor genomics profiling for treatment selection
Recent Developments
(June 2025) Rebranded to Insight Molecular Diagnostics Inc. and relocated HQ to Nashville, Tennessee
(May 2025) Announced improved reimbursement rates for GraftAssureCore transplant diagnostic test
(Q1 2025) Generated $2.1 million in pharma services revenue with 62% gross margin
Open the full interactive Insight Molecular Diagnostics Inc. (formerly OncoCyte Corporation) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.